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The muscular dystrophies are broadly classified as muscle wasting
diseases with myofiber dropout due to cellular necrosis, inflam-
mation, alterations in extracellular matrix composition, and fatty
cell replacement. These events transpire and progress despite
ongoing myofiber regeneration from endogenous satellite cells.
The degeneration/regeneration response to muscle injury/disease
is modulated by the proinflammatory cytokine transforming
growth factor-β (TGF-β), which can also profoundly influence ex-
tracellular matrix composition through increased secretion of pro-
fibrotic proteins, such as the matricellular protein periostin. Here
we show that up-regulation and secretion of periostin is patho-
logical and enhances disease in the δ-sarcoglycan null (Sgcd−/−)
mouse model of muscular dystrophy (MD). Indeed, MD mice lack-
ing the Postn gene showed dramatic improvement in skeletal mus-
cle structure and function. Mechanistically, Postn gene deletion
altered TGF-β signaling so that it now enhanced tissue regenera-
tion with reduced levels of fibrosis. Systemic antagonism of TGF-β
with a neutralizing monoclonal antibody mitigated the beneficial
effects of Postn deletion in vivo. These data suggest that periostin
functions as a disease determinant in MD by promoting/allowing
the pathological effects of TGF-β, suggesting that inhibition of
periostin could represent a unique treatment approach.
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Muscular dystrophy (MD) broadly encompasses a diversegroup of genetic disorders that result in loss of muscle
fibers, leading to progressive skeletal muscle weakness, dilated
cardiomyopathy, and premature death (1). The majority of ge-
netic mutations identified in patients with MD appear to affect
the multiprotein sarcolemmal-spanning dystrophin-glycoprotein
complex, which is critical for stabilization of the membrane and
prevention of calcium overload, leading to myofiber death and
an inflammatory response (2). One such inflammatory mediator,
transforming growth factor (TGF)-β, is thought to worsen MD
and lead to increased fibrosis in human dystrophic muscle (3, 4)
and animal models of dystrophy (5); for example, administration
of decorin (a TGF-β antagonist) reduces collagen expression in
the diaphragm of dystrophin-deficientmdxmice (6), and losartan
(an angiotensin II type 1 receptor blocker thought to reduce
TGF-β activity) normalizes muscle architecture and improves
function in animal models of myopathy (7, 8). Recently, genetic
alterations in the TGF-β pathway, such as changes in latent
TGF-β binding protein 4, also have supported the theory of
a strong interplay between TGF-β–induced fibrosis and MD se-
verity (9). In vitro, TGF-β can directly influence satellite cell
proliferation, myocyte differentiation, and myofiber fusion (10).
Periostin is a 90-kDa secreted extracellular matrix (ECM)
protein that has been proposed to function upstream and
downstream of TGF-β (11). It contains four fasciclin domains
that are also observed in the insect protein fasciclin I, which is
involved in neuronal cell–cell adhesion (11, 12). Periostin ex-
pression is low at baseline in many adult tissues, but is strongly
induced and secreted into the ECM after acute injury, as well as
in dystrophic skeletal muscle (13). Periostin is expressed exclu-
sively by fibroblasts or cells that adopt a fibroblast-like phenotype
after an injurious event (14). In the heart, we and others have
shown that periostin is strongly induced after myocardial in-
farction and left ventricular pressure overload, where it plays
a role in ECM remodeling and healing (15, 16).
In the present study, we found that mice lacking periostin
(Postn) were profoundly protected from MD through mecha-
nisms involving decreased fibrosis and enhanced myofiber re-
generation in conjunction with increased TGF-β activity.
Although inhibition of TGF-β is typically protective in MD, the
protection that we observed in dystrophic mice lacking Postn was
reversed by administration of a TGF-β–blocking antibody, sug-
gesting another example of the so-called “TGF-β paradox” (17).
Thus, therapeutic manipulation of periostin may offer another
means of altering MD disease progression when TGF-β re-
sponsiveness is targeted.
Results
Periostin Is Induced in Dystrophic Skeletal Muscle. Periostin is nor-
mally expressed in low amounts in adult tissues, but expression is
dramatically increased after, for example, myocardial infarction
simultaneously with the fibrotic response and scar formation
(16). MD is characterized by ECM remodeling, fibrosis, and
progressive scarring in skeletal muscle, suggesting that periostin
could be similarly involved. Indeed, biopsy material from human
skeletal muscle of a patient with Duchenne MD showed peri-
ostin accumulation by immunohistochemistry in the ECM within
an area of myofiber dropout (Fig. 1A). Similarly, we also ana-
lyzed Sgcd−/− mice, a model of MD that arises due to deletion of
the δ-sarcoglycan protein (18). Serum from these mice demon-
strated increased circulating levels of periostin by ELISA (Fig.
1B), as well as by Western blot analysis of diseased skeletal
muscle (Fig. 1C). Immunohistochemistry analysis revealed pro-
found induction and accumulation of periostin in the ECM of
the diaphragm, gastrocnemius, and quadriceps at 6 wk and 6 mo
of age (Fig. 1D). In the heart, cardiac fibroblasts were found to
be the source of periostin; thus, to discern the cell type
expressing periostin in our dystrophic model, we used a trans-
gene containing the periostin promoter driving ZsGreen. We
observed that only the interstitial cells expressed periostin in
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dystrophic skeletal muscle (Fig. 1E). Immunohistochemistry
showed that the ZsGreen signal overlapped with ∼70–80% of the
resident fibroblasts as marked with a pan-fibroblast polyclonal
antisera, anti-vimentin, and α-smooth muscle actin for activated
fibroblasts (Fig. S1). These data indicate that periostin is induced
in fibroblasts in diseased skeletal muscle.
Deletion of Periostin Ameliorates MD Histopathology in Sgcd−/−Mice.
We hypothesized that the ablation of Postn would reduce the
pathogenesis of MD by limiting fibrosis, thereby enhancing
ongoing regeneration or perhaps limiting the inflammatory
response. Indeed, deletion of Postn in the Sgcd−/− mouse
background showed substantially less histopathology at both 6
wk and 6 mo of age in the diaphragm, gastrocnemius, and
quadriceps compared with Sgcd−/−mice, whereas Wt and Postn−/−
mice demonstrated no disease (Fig. S2). An increase in muscle
weight due to pseudohypertrophy is associated with MD; this was
observed in muscles from Sgcd−/− mice at 6 wk and 6 mo of age,
but not in Sgcd−/−Postn−/− mice (Fig. 2 A and B). Interestingly,
quantification of central nucleation from histological muscle
sections, which typically reflects ongoing myofiber regeneration
or the total amount of damage, showed equal or elevated levels
in Sgcd−/−Postn−/− mice compared to Sgcd−/− mice, suggesting
that loss of Postn did not limit myofiber regeneration or damage
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Fig. 1. Evaluation of periostin expression in Sgcd−/− mice. (A) Immunohistochemistry showing periostin (green) localization in muscle biopsy specimens from
normal patients and patients with Duchenne MD (DMD). (Original magnification: 600×; scale bar: 50 μm.) (B) Periostin levels, detected by ELISA, in the serum
of 6-wk old WT (Wt) and Sgcd−/−mice. *P < 0.05. n = 4 mice each. (C) Western blot for periostin in Wt and Sgcd−/−mice from the diaphragm at 6 wk and 6 mo
of age. GAPDH was used as a loading control. (D) Immunohistochemistry showing increased periostin (green) in areas of fibrosis in the diaphragm (diaph.),
gastrocnemius (gastroc.), and quadriceps (quad.) of Wt and Sgcd−/−mice at 6 wk and 6 mo of age. Membranes are stained in red with wheat germ agglutinin
conjugated to TRITC, and nuclei are stained with DAPI (blue). (Original magnification: 400×; scale bar: 100 μm.) (E) Immunohistochemistry showing ZsGreen
staining (green) of the gastrocnemius in Sgcd−/− and Sgcd−/−Postn-ZsGreen TG mice. The ZsGreen-positive cells express periostin. Wheat germ agglutinin was
conjugated to TRITC (red) and To-Pro nuclei (blue). Error bars represent SEM.
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Fig. 2. Genetic deletion of periostin diminishes the pathology in Sgcd−/− muscle. (A and B) Muscle weights normalized to tibia length from the quadriceps,
gastrocnemius, and diaphragm in the indicated groups of mice at 6 wk and 6 mo of age. (C) Quantification of the percent of fibers containing central nuclei in
the gastrocnemius from 6-wk-old and 6-mo-old mice. (D) Fiber areas from the gastrocnemius of the indicated mice separated into ranges. Error bars represent
SEM.*P < 0.05 vs. Wt; #P < 0.05 vs. Sgcd−/−. The numbers of mice or muscles analyzed are shown in the bars.
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(Fig. 2C). Myofibers from Sgcd−/−Postn−/− mice were signifi-
cantly larger across different ranges of cross-sectional areas
compared with those from Sgcd −/− mice, suggesting more or-
derly regeneration, likely due to less tissue fibrosis and patho-
logical ECM remodeling (Fig. 2D). Indeed, direct assessment
of tissue fibrosis with Masson’s trichrome histological staining of
diaphragm, gastrocnemius, and quadriceps at 6 wk and 6 mo of
age showed significant reductions in Sgcd−/−Postn−/− mice com-
pared with single-null Sgcd mice (Fig. 3 A–C). Measurement of
total tissue hydroxyproline content in the quadriceps confirmed
these histological findings (Fig. 3D). Along with less fibrosis,
skeletal muscle from Sgcd−/−Postn−/− mice showed a dramatic
up-regulation in the expression and activity of matrix metal-
loproteinase 9 (MMP9), which enhances ECM turnover to
maintain tissue plasticity and beneficial remodeling (Fig. 3 E
and F). Other positive effects observed in skeletal muscle from
double-null mice compared with single-null Sgcd mice included
reduced mRNA levels of collagen 5α3 and 1α2 (Fig. 3G). Col-
lectively, these results suggest that loss of Postn improves skeletal
muscle tissue pathology through beneficial ECM remodeling and
reduced fibrosis, as well as enhanced regeneration.
Deletion of Postn Ameliorates Broader Indexes of MD in Sgcd−/−
Mice. In addition to less pathology at the histological level in
skeletal muscle, Sgcd−/−Postn−/− mice showed a profound re-
duction in total serum creatine kinase levels at age 6 wk and
6 mo compared with Sgcd−/− mice, suggesting less myofiber
membrane ruptures, possibly due to more uniform ECM prop-
erties with less inflammation (Fig. 4 A and B). This profile of
healthier skeletal muscle in Sgcd−/−Postn−/− mice compared to
Sgcd−/− mice also correlated with better functional performance;
the double-null mice exercised significantly longer with forced
treadmill running compared with the single-null Sgcd mice (Fig.
4 C and D). Collectively, these results indicate that deletion of
Postn enhances myofiber integrity in Sgcd deleted mice, resulting
in better functional performance.
Although serum creatine kinase levels were reduced in Sgcd−/−
Postn−/− mice compared with single-null Sgcd mice, suggesting
fewer membrane ruptures, overall levels of myofiber turnover
were likely the same in the two types of mice, given that central
nucleation was either the same or even enhanced in the double-
null mice (Fig. 2C). Indeed, quantitation of myofibers expressing
embryonic myosin heavy chain (eMHC) or myogenin, which
demarcates newly regenerated fibers, showed higher levels in
Sgcd−/−Postn−/− mice compared with single-null Sgcd mice, sug-
gesting enhanced regeneration (Fig. 5A). The simplest in-
terpretation of all of the data presented to this point is that
myofiber degeneration is no different between Sgcd−/−Postn−/−
mice and single-null Sgcd mice. However, by reducing the accu-
mulation of fibrotic material, ECM “health” is maintained, which
permits greater levels of ongoing regeneration with fewer sec-
ondary ruptures in myofiber membranes. Such observations also
should be consistent with less ongoing inflammation, which we
examined directly in this study. Indeed, Sgcd−/−Postn−/− mice had
significantly fewer macrophages in histological sections from
skeletal muscles compared with single-null Sgcdmice (Fig. 5 B–D).
Altered TGF-β Signaling Underlies Periostin-Dependent Effects on MD.
Periostin expression is known to be induced by TGF-β and to
affect TGF-β signaling. Thus, we analyzed TGF-β levels and the
activation of downstream transcription factors, such as Smad2/3,
that are regulated by TGF-β. Inhibition of TGF-β has been
shown to reduce aspects of MD disease in skeletal muscle, be-
cause it is typically induced during MD, as we confirmed here in
Sgcd−/− muscle (6–8) (Fig. 5E). More importantly, deletion of
Postn in the Sgcd−/− background led to significantly higher
TGF-β levels in skeletal muscle (Fig. 5E). Consistent with these
results, use of a phospho-specific Smad2/3 antibody on muscle
histological sections produced greater levels of activation in
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Fig. 3. Analysis of the ECM in skeletal muscle. (A) Representative Masson’s trichrome-stained diaphragm, gastrocnemius, and quadriceps from WT, Postn−/−,
Sgcd−/−, and Sgcd−/−Postn−/− mice at 6 mo of age. (Original magnification: 100×.) (B and C) Quantification of fibrotic area by Masson’s trichrome staining at
6 wk and 6 mo of age. The number of muscles analyzed is shown in the bars. (D) Measurement of hydroxyproline content in the quadriceps fromWT, Sgcd−/−,
and Sgcd−/−Postn−/− mice expressed as micrograms of hydroxyproline per milligram of tissue. (E) Western blot analysis for MMP9 in the indicated groups of
mice from the gastrocnemius at 6 wk of age. GAPDH was used as a loading control. (F) MMP9-specific activity assay from the gastrocnemius of the indicated
mice (6 wk of age). n = 3 or more for each group. (G) Real-time PCR from quadriceps muscle of the indicated mRNA in Sgcd−/− vs. Sgcd−/−Postn−/−mice. mRNA
levels were normalized to 18s RNA. Error bars represent SEM. *P < 0.05 vs. WT; #P < 0.05 vs. Sgcd−/−. The number of mice analyzed is shown in or above
the bars.
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Sgcd−/−Postn−/− mice compared with single-null Sgcd mice at
6 wk of age, suggesting enhanced TGF-β signaling (Fig. 5 F and
G). To mechanistically assess whether this increase in TGF-β
influencesd the protection observed in skeletal muscle of Sgcd−/−
Postn−/− mice, we used a TGF-β–blocking monoclonal antibody as
a systemic treatment. Six weeks of this treatment lead to a de-
crease in Smad2/3 phosphorylation in skeletal muscle of Sgcd−/−
Postn−/− mice, indicating nearly complete inhibition of TGF-β
signaling (Fig. 6A). As suggested previously in the literature,
treatment of mdx mice with the TGF-β pathway inhibitor losartan
partially mitigated MD phenotypic manifestations (7, 8). In con-
trast, inhibition of TGF-β signaling in Sgcd−/−Postn−/− mice sig-
nificantly worsened muscle function, such that these mice now had
reduced exercise capacity compared with those receiving vehicle
treatment (Fig. 6B). The deleterious effects of TGF-β blockade in
the Sgcd−/−Postn−/− mice may be related to the TGF-β paradox
described in the oncology literature (17), which in skeletal muscle
may reflect an interplay between myofiber regeneration versus
ongoing fibrosis and ECM remodeling. Indeed, assessment of re-
generation by reexpression of MyoD, myogenin, and Pax7 in the
different groups of mice suggested that TGF-β–neutralizing anti-
body enhanced regeneration in single-null Sgcdmice, but inhibited
regeneration in Sgcd−/−Postn−/− mice (Fig. 6C).
The foregoing results suggest that in the absence of Postn,
TGF-β signaling is altered so as to support regeneration without
an increase in tissue fibrosis. To more directly examine this
concept, we analyzed regeneration in Postn−/− mice versus WT
mice over a 21-d period after freeze injury. Periostin protein
induction was evident within 3 d after freeze injury, became more
elevated by 7 d, and then was nearly absent by 21 d (Fig. 6D).
Assessment of eMHC- and myogenin-positive fibers in the area
of freeze injury suggested greater myofiber regeneration in
Postn−/− muscle compared with WT muscle, as well as a greater
percentage of the smaller regenerative myofibers (<100 μm2)
(Fig. 6 E–G). Gross histological assessment of the injury area
also demonstrated faster and more complete healing in Postn−/−
muscle after freeze injury compared with WT controls. These
findings indicate that loss of Postn leads to improved myofiber
regeneration in conjunction with a reprogramming of TGF-β
function in diseased skeletal muscle.
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Discussion
The data presented here provide genetic evidence supporting the
role of periostin in the pathogenesis of skeletal muscle injury,
and marks this protein as a therapeutic target for the manage-
ment of MD. Although this is unique in describing the benefit of
Postn deletion in injured skeletal muscle, our results are con-
sistent with, and provide mechanistic insight into, previous
studies of cardiac muscle injury. In those studies, mice lacking
Postn were much more likely to die after myocardial infarction
injury due to a deficit in the fibrotic process and the inability to
form a proper scar, which led to wall rupture; however, mice
lacking Postn also demonstrated preserved cardiac function with
long-term disease-inducing stimuli, likely because of less patho-
logical remodeling of the ECM and accumulation of fibrotic
material (15, 16). Previous work has strongly supported a direct
interaction between periostin and ECM proteins such as fibro-
nectin, tenascin-C, collagen I, collagen V, and heparin (19),
suggesting that secretion of periostin might change the proper-
ties of these proteins or their assembly in the ECM. Indeed, the
strength of collagen in the ECM is reduced in Postn-deficient
mice (20, 21). Similar to the cardiac data, dystrophic mice de-
ficient in Postn also exhibit beneficial changes in function, as well
as dramatically decreased fibrosis. These observations suggest
that the induction of periostin could be correlated with muscle
pathology and disease severity in humans. To directly examine
this, in previous work we queried the expression of periostin
mRNA in a dataset of 125 human muscle biopsy specimens (22,
23). Of the 10 muscle diseases studied, nearly all were associated
with increased periostin levels relative to normal muscle (Fig.
S3). The most significant increases were in patients with Du-
chenne MD (P < 0.0001) and juvenile dermomyositis (P <
0.0001). Furthermore, the literature supports that the increase
in periostin mRNA levels in Duchenne MD muscle is age-
dependent and is elevated most significantly (a twofold increase)
in young children (24).
Our results indicate that periostin negatively impacts disease
pathogenesis in MD, such that its deletion enhances myofiber
regeneration. These observations are superficially in direct op-
position to a previous report in which direct application of
a truncated version of periostin protein onto infarcted rodent
hearts led to increased healing of the injury by induction of re-
generation and cell cycle reentry of cardiomyocytes (25). How-
ever, a follow-up to that study found that overexpression of full-
length periostin in vitro and in vivo did not alter the regeneration
ability of the cardiomyocytes (26). Furthermore, periostin-over-
expressing hearts (full-length protein) showed either baseline
pathology or an increase in long-term fibrosis or hypertrophy, or
worsening function with disease stimulation (16, 27). One in-
teresting possibility that could explain the discordance between
these studies is if the truncated version of periostin used by Kuhn
et al. (25) actually had some sort of inhibitory activity toward
periostin function, given that it lacks part of the N terminus and
more than 140 amino acids of the C terminus. If this truncated
version of periostin indeed disrupted key interactions observed
with the full-length protein, such as its interaction with other
ECM proteins, integrins, or even TGF-β, this would suggest
a possible therapeutic advantage of applying this peptide to areas
of injury as a periostin antagonist. Regardless of the reasons, our
current results clearly demonstrate that loss of periostin is of
benefit to diseased skeletal muscle in association with better
myofiber regeneration, consistent with the results reported by
Oka et al. (16) and Lorts et al. (26), in which hearts of periostin-
overexpressing mice did not exhibit greater regeneration and
were predisposed to disease.
We hypothesized that the changes in the ECM of Postn−/−
mice allow for a more stable and favorable milieu for myocyte
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Smad2/3 in the quadriceps showing the nearly complete loss of signal in Sgcd−/−Postn−/− mice injected with TGF-β neutralizing antibody. Original magnifi-
cation: 600×; scale bar: 50 μm.) (B) Time to fatigue in seconds with forced downhill treadmill running in the indicated groups of mice injected with anti–TGF-β
or vehicle. #P < 0.05, Sgcd−/−Postn−/− vehicle vs. anti-TGF-β. (C) Western blots for MyoD, myogenin, periostin, and Pax7 in the gastrocnemius of the indicated
groups of mice, injected or not injected with TGF-β antibody. GAPDH was used as a loading control. (D) Immunohistochemistry showing increased periostin
(green) staining after 7 d of freeze injury in the gastrocnemius muscle. Red staining was with WGA-TRITC, and blue denotes nuclei (DAPI). (Original mag-
nification: 400×; scale bar: 100 μm.) (E) Quantification of eMHC-positive fibers in the injured area of WT and Postn−/− mice after 7 d of injury. (F) Quanti-
fication of myogenin-positive nuclei in the injured area of WT and Postn−/− mice after 7 d of injury. (G) Fiber areas from the peri-injury area in the
gastrocnemius of WT and Postn−/− mice, separated into ranges. *P < 0.05 vs. WT; #P < 0.05 vs. vehicle. Error bars represent SEM. The numbers of mice or
individual muscles examined are shown in or above the bars throughout the figure.
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regeneration. This hypothesis is supported by previously pub-
lished data showing that Postn−/− mice have disorganized and
dysfunctional collagen fibrils, leading to a less rigid ECM (21). In
the oncologic literature, periostin has been shown to affect the
ability of cells to migrate and metastasize (28), and the lack of
periostin in damaged muscle may encourage mobilization and
migration of satellite cells throughout the area of injury. Con-
sistent with this working hypothesis, TGF-β is known to stimulate
periostin secretion (11, 29), and inhibition of TGF-β leads to
decreased periostin expression (7). In both skeletal and cardiac
muscle, manipulation of TGF-β via a neutralizing antibody or
treatment with losartan leads to improvement in muscle function
and histology and, coincidently, a decrease in periostin in the
muscle (7, 30). These results are consistent with the hypothesis
that TGF-β secretion and its enhanced activity contribute to the
demise of skeletal muscle in MD (9). However, one interesting
possibility is that periostin functions as a key downstream ef-
fector of TGF-β that promotes its deleterious effects in MD (31).
Indeed, in the absence of periostin, TGF-β appears to have
a protective effect in MD disease progression by enhancing re-
generation or by blunting other negative effects of this cytokine
(14). The use of the TGF-β–blocking antibody worsened MD
and resulted in greater functional decline in double-null mice.
These findings support a complex interaction between periostin
and TGF-β that may be related to the TGF-β paradox, where it
can be both beneficial and deleterious depending on dosage and
costimulatory factors (17).
Periostin expression in epithelial cells has been shown to
stimulate TGF-β signaling and lead to enhanced collagen pro-
duction and expression of matrix metalloproteinase 2 and MMP9
for further matrix remodeling (31). Thus, periostin may in-
directly alter TGF-β–dependent disease signaling by changing
the composition of the ECM with respect to other known TGF-
β–binding proteins that reside there, such as the latent TGF-β–
binding proteins, fibrillins, and thrombospondin-1, as well as by
effecting interactions with select integrins that alter the function
of latency-associated peptides in controlling how TGF-β is acti-
vated and presented to receptors on surrounding cells (32).
Perturbation of TGF-β activity has been strongly implicated in
the pathogenesis of diverse disease states, including MD. The
incorporation of TGF-β antagonism into therapeutic strategies
remains controversial, given the known mix of beneficial and
deleterious effects. Our data presented here reveal the com-
plexity of TGF-β signaling and suggest that selective targeting of
downstream mediators of TGF-β, such as antiperiostin thera-
peutics, may be more optimal than global TGF-β inhibition.
Methods
Postn null mice were generated and characterized previously (19), as was
the MD mouse model with deletion of the δ-sarcoglycan gene (21). Two mg/
kg of TGF-β–blocking antibody (R&D Systems) was used in the blocking
experiments and was given once a wk for a period of 6 wk. Histological
analysis was performed using standard techniques, as elaborated in
SI Methods.
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